My question: Do deep research and support and/or refute the following: High-purity oral spermidine up to 40 mg/day does not meaningfully raise systemic spermidine levels due to rapid conversion to spermine.
I was exploring this in OpenEvidence a few weeks back, and it clarified that serum levels are a poor indicator of spermidine bioavailability because spermidine is rapidly taken up into tissues (compartmentalization) and therefore the compound actually has 70-80% bioavailability which is quite high but is not reflected in serum.
Chat answer. (34 seconds.): High-purity oral spermidine up to 40 mg/day does not reliably increase circulating spermidine concentrations in humans. Some of the dose appears to be metabolized to spermine, and plasma/serum spermidine is clearly an imperfect marker of whole-body polyamine biology. However, the claim that oral spermidine has 70–80% systemic bioavailability in humans because it is rapidly sequestered into tissues is not presently established.
Does oral spermidine raise blood spermidine?
Two controlled human studies suggest that it does not raise it very much, if at all.
A 2023 randomized, triple-blind crossover pharmacokinetic study gave 12 healthy adults 15 mg/day for five days. Plasma spermidine exposure was essentially unchanged: AUC was 1533 h·ng/mL with placebo versus 1567 with spermidine, p=0.78. Plasma spermine exposure, however, rose significantly from 584 to 633 h·ng/mL, p=0.028. The investigators therefore proposed substantial presystemic conversion of ingested spermidine to spermine.
A larger 2024 randomized study gave 37 healthy men aged 50–70 high-purity spermidine at 40 mg/day for up to 28 days. Again, there were no substantial increases in serum spermidine or spermine. The authors described this as evidence of strong homeostatic control of circulating polyamines.
This phenomenon also appears with dietary spermidine. In a one-year natto intervention, dietary spermidine intake increased substantially, but whole-blood spermidine did not; spermine rose modestly instead.
Therefore, the first part of the proposition is well supported: even 15–40 mg/day does not translate into a large sustained elevation in plasma or serum spermidine.
Is conversion to spermine the explanation?
Probably partly, but not completely.
The 15-mg pharmacokinetic study provides the strongest human evidence for this: spermine exposure increased while spermidine did not. The investigators proposed that spermidine is absorbed into intestinal cells and then converted by spermine synthase, either in intestinal cells or during hepatic first-pass metabolism. Spermine could subsequently be converted back to spermidine within peripheral tissues.
That mechanism is biologically credible because mammalian polyamine metabolism is highly dynamic. Spermidine and spermine exist within a tightly regulated network involving synthesis, interconversion, oxidation, acetylation, cellular transport and export.
However, it would be too strong to say that rapid conversion to spermine completely explains what happens to a 40-mg oral dose. In the 40-mg study, neither circulating spermidine nor spermine rose substantially after 28 days.
Several processes may therefore operate simultaneously:
- Presystemic conversion of spermidine to spermine.
- Cellular and tissue uptake.
- Acetylation and degradation.
- Urinary elimination.
- Compensatory suppression of endogenous polyamine synthesis.
- Strong intracellular homeostatic regulation.
The 2026 literature discussed in a human muscle study also notes that the 40-mg trial showed increased urinary spermidine and spermine at an early measurement despite little change in serum concentrations.
Thus, conversion to spermine is supported, but the proposition that most or all of the administered spermidine is immediately converted to spermine is not established.
Is serum spermidine a poor indicator because spermidine is compartmentalized into tissues?
This part of the OpenEvidence interpretation is substantially correct, with an important qualification.
A particularly informative 2026 study measured both circulating and actual skeletal-muscle polyamines in 192 older patients, including muscle biopsies from 101 subjects.
Median concentrations were approximately:
- Plasma spermidine: 21 ng/mL.
- Muscle spermidine: 7,120 ng/g.
- Plasma spermine: 15.1 ng/mL.
- Muscle spermine: 48,000 ng/g.
Most importantly, plasma spermidine did not correlate with skeletal-muscle spermidine. Dietary spermidine intake also did not correlate with muscle spermidine concentration.
The investigators concluded that skeletal-muscle polyamine pools are subject to strong intracellular regulation and that plasma provides only a limited indication of tissue polyamine status.
That provides substantial support for an important conclusion:
A normal or unchanged plasma spermidine concentration cannot be interpreted as evidence that tissue polyamine biology is unchanged.
Polyamines are predominantly intracellular molecules. They interact with RNA, DNA, proteins, phospholipids and other negatively charged cellular structures. Plasma represents a comparatively small and tightly regulated compartment.
There is nevertheless an important limitation. The 2026 muscle study was cross-sectional. It does not demonstrate that taking a 30- or 40-mg spermidine supplement causes a large fraction of that dose to accumulate in skeletal muscle or other tissues. In fact, habitual dietary spermidine intake was not associated with muscle spermidine concentrations.
Therefore, evidence for tissue compartmentalization does not establish the fate of a particular oral dose.
What about the claim of 70–80% bioavailability?
This is the part of the argument that I would refute, or at least substantially qualify.
The frequently cited figure appears to originate primarily from a 2003 rat experiment rather than from human oral pharmacokinetic studies. Investigators placed radiolabeled polyamines directly into the jejunum of an isolated perfused rat intestine and recovered approximately 61–76% of the radioactive signal in portal venous blood during the first 10 minutes.
That is evidence that polyamines can be efficiently absorbed across the rat small intestine.
It does not establish 70–80% absolute oral bioavailability of unchanged spermidine in humans. There are several reasons:
- The experiment involved rats rather than humans.
- It used an isolated intestinal preparation.
- Spermidine was placed directly into the jejunum rather than swallowed normally.
- Recovery of radioactive material does not necessarily mean that all recovered material remained unchanged spermidine.
- Normal gastric processing and systemic disposition were not reproduced.
- The experiment did not measure human tissue exposure.
Interestingly, the investigators conducting the 2023 human pharmacokinetic study specifically discussed this approximately 61–76% rat intestinal recovery while emphasizing that their human results indicated extensive presystemic metabolism.
Consequently, I would not describe oral spermidine as having “70–80% bioavailability” in humans.
A more defensible statement is:
Spermidine appears to be efficiently absorbed by the intestine in animal models, but the absolute oral bioavailability of unchanged spermidine has not been established in humans.
There is another interesting nuance in the 2026 human data. Habitual dietary spermidine intake did have a statistically significant association with plasma spermidine: approximately doubling dietary intake was associated with roughly an 18–26% higher plasma concentration, depending upon statistical adjustment.
However, dietary intake explained very little of the variability in circulating spermidine, and there was no corresponding relationship with muscle spermidine concentrations.
This argues against both extreme interpretations.
The statement that “oral spermidine isn’t absorbed because blood spermidine doesn’t rise” is not justified.
But the opposite statement that “spermidine is 70–80% bioavailable and disappears from plasma because most of it rapidly enters tissues” is also not demonstrated.
What does this mean for a 30-mg/day dose?
The evidence currently supports the following conclusions.
A 30-mg daily dose probably should not be expected to produce a substantial sustained increase in plasma spermidine.
The absence of such an increase does not demonstrate that the supplement was not absorbed.
Some oral spermidine is probably converted to spermine before or shortly after reaching the systemic circulation.
Blood spermidine is a poor surrogate for tissue spermidine stores.
It is biologically plausible that tissue uptake accounts for part of the discrepancy between oral intake and circulating levels, but human studies have not established what percentage of a 30-mg dose enters tissues.
Human oral bioavailability of 70–80% has not been demonstrated.
Most importantly, there is currently no good evidence establishing that 30–40 mg/day produces greater autophagy, eIF5A hypusination, cognitive, cardiovascular or longevity benefits than substantially lower doses.
Short-term studies indicate that 40 mg/day can be tolerated in adults aged 50–70, but that is quite different from demonstrating the long-term safety of 30–40 mg/day.
The lower-dose clinical efficacy literature isn’t particularly strong either. The 12-month SmartAge trial using approximately 0.9–1.2 mg/day did not significantly improve its primary memory outcome. Epidemiologic studies associate higher dietary spermidine intake with lower mortality, but observational associations cannot establish that supplemental spermidine causes longer life.
Overall conclusion
The OpenEvidence conclusion that serum is a poor standalone measure of spermidine exposure is well supported and has become more convincing with the 2026 human muscle-biopsy evidence.
The assertion that failure to raise serum spermidine demonstrates poor intestinal absorption should therefore be rejected.
However, the specific claim that oral spermidine has 70–80% bioavailability in humans appears to be an extrapolation primarily from animal intestinal-absorption experiments and should not currently be regarded as established human pharmacokinetics.
I would therefore rewrite the original proposition as follows:
High-purity oral spermidine at doses up to 40 mg/day does not substantially raise circulating spermidine in short-term human studies. At least part of an oral dose appears to undergo presystemic conversion to spermine, while tissue uptake and other tightly regulated metabolic pathways may also account for the weak plasma signal. Circulating spermidine is therefore an incomplete measure of tissue polyamine status.
For your current 30 mg/day dose, the more consequential question is therefore not whether the spermidine is absorbed. It is whether 30 mg/day provides meaningfully greater biological effects—particularly autophagy and eIF5A hypusination—than 10–15 mg/day, and whether there is evidence supporting that higher dose for long-term use at age 80. That is a separate dose-response question, and the available evidence is considerably less certain.